FDA CBER Issues Landmark Draft Guidance: 'Leveraging Prior Knowledge in Gene Therapy Products Incorporating Genome Editing' — First Regulatory Framework to Accelerate CRISPR Pipeline via Platform Data Cross-Referencing

On June 2, 2026, FDA's Center for Biologics Evaluation and Research (CBER) published a landmark draft guidance document titled 'Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing.' Published in the Federal Register on June 3 (FR Doc. 2026-11054), this is the first FDA guidance specifically designed to reduce duplicative regulatory studies across the rapidly expanding genome-editing therapeutic pipeline. The guidance enables sponsors of both ex vivo and in vivo CRISPR and other genome-editing gene therapies to reference publicly available platform data in new regulatory submissions — including chemistry, manufacturing and controls (CMC) data, prior platform nonclinical findings, and existing clinical evidence from comparable gene editing approaches — rather than requiring full repeat studies for each new program. CBER Acting Director Karim Mikhail stated: 'By providing information on how companies may build on what is already known, we are accelerating innovation without compromising the rigorous scientific standards that patients and the public depend on.' Acting Director of the Office of Therapeutic Products Vijay Kumar added: 'Leveraging prior knowledge does not mean lowering the bar; it means raising our collective efficiency.' The guidance is particularly significant for the CRISPR field, where multiple companies (Intellia, Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, Prime Medicine) are pursuing LNP-based and ex vivo gene editing therapies sharing common delivery platforms and editing mechanisms. Cross-referencing CMC and safety data already established by lead programs — such as Casgevy (approved, ex vivo CRISPR) and lonvo-z (rolling BLA, in vivo CRISPR) — could meaningfully reduce IND and BLA development timelines and costs for follow-on programs. The guidance applies to genome-editing gene therapies including those using CRISPR-Cas systems, zinc finger nucleases, TALENs, base editors, and prime editors. The public comment period runs 90 days from Federal Register publication, closing approximately September 1, 2026.